Valneva SE

113 articles with Valneva SE

• Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001

  3/2/2023

  Valneva SE, a specialty vaccine company, announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001.

• Valneva to Present at the Cowen 43rd Annual Healthcare Conference

  3/1/2023

  ValnevaSE announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Cowen 43rd Annual Healthcare Conference, to take place in-person March 6 - 8, 2023 in Boston, Massachusetts.

• 

  Pfizer/Valneva Trial at Risk After Possible GCP Violations

  2/17/2023

  Pfizer and Valneva are dropping approximately half of enrolled participants in the Phase III VALOR study for their Lyme disease vaccine candidate, VLA15.

• Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

  2/17/2023

  Pfizer Inc. and Valneva SE announce that Pfizer, as the study sponsor, has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists Phase 3 clinical study.

• Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance

  2/16/2023

  Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2022 and provided first full year 2023 sales guidance.

• Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

  2/14/2023

  Valneva SE, a specialty vaccine company, announced that it completed enrollment and vaccination for a Phase 3 trial in adolescents, VLA1553-321, of its single-shot chikungunya vaccine candidate, VLA1553.

• Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine

  12/30/2022

  ValnevaSE, a specialty vaccine company, reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.

• Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

  12/21/2022

  Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team including Thomas Lingelbach, CEO and Peter Bühler, CFO will hold investor meetings during the 41st Annual J.P. Morgan Healthcare Conference, January 9 – 12, 2023 in San Francisco and the Oddo BHF Forum, January 5 - 6, 2023 in Lyon France.

• Valneva Hosts Investor Day in New York City - December 06, 2022

  12/6/2022

  Saint-Herblain, December06, 2022 – Valneva SE, a specialty vaccine company, is hosting an in-person investor day in New York City to discuss the Company’s current vaccine pipeline, commercial products, and future directions.

• Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

  12/1/2022

  Pfizer Inc. and Valneva SE reported antibody persistence data six months after the completion of a three-dose or a two-dose vaccination schedule with their Lyme disease vaccine candidate, VLA15 in both children and adults.

• Valneva to Host Investor Day in New York City - November 29, 2022

  11/29/2022

  Valneva SE, a specialty vaccine company, announced it will host an in-person investor day in New York City to discuss the Company’s current vaccine pipeline, commercial products, and future directions from 10:00 AM to 12:00 PM ET on Tuesday, December 6, 2022.

• 

  Movers & Shakers: IPI, Lucy Therapeutics, Valneva and More Add New Leaders

  11/18/2022

  With the Thanksgiving season upon us, there are many reasons for biopharma and life sciences companies to say thanks, including for new leaders. 

• Valneva Appoints Dipal Patel as Chief Commercial Officer

  11/17/2022

  ValnevaSE, a specialty vaccine company, announced the appointment of Dipal Patel as Chief Commercial Officer and Management Board member.

• 

  Beyond COVID-19 and RSV, Emerging Vaccines Target Less Common Conditions

  11/16/2022

  RSV, influenza, COVID-19 and monkeypox have dominated vaccine discussions this year, but vaccines are also being developed for a host of other infectious diseases.

• Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates

  11/10/2022

  Valneva SE reported consolidated financial results for the first nine months of the year, ended September 30, 2022.

• Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

  11/7/2022

  ValnevaSE announced that its Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will present and participate in 1-on-1 meetings with institutional investors at the Jefferies London Healthcare Conference, to take place November 15-17, 2022 in London, England.

• Valneva Announces Closing of Upsized €102.9 Million Global Offering

  10/4/2022

  Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, announced today the closing of its previously announced global offering to specified categories of investors of an aggregate 21,000,000 new ordinary shares.

• Valneva Announces Pricing of €102.9 Million Global Offering of American Depositary Shares and Ordinary Shares

  9/30/2022

  Valneva SE announced the pricing of 21,000,000 ordinary shares in a global offering to specified categories of investors comprised of a public offering of 375,000 American Depositary Shares, each representing two ordinary shares, in the United States and a concurrent private placement of 20,250,000 ordinary shares in certain jurisdictions outside of the United States.

• Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

  9/28/2022

  Valneva SE announced its intention to issue and sell, subject to market conditions, approximately $40 million of its ordinary shares in a global offering to specified categories of investors comprised of a public offering of its American Depositary Shares, each representing two ordinary shares, in the United States and a concurrent private placement of its ordinary shares in certain jurisdictions outside of the United States.

• Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

  9/8/2022

  Valneva SE and VBI Vaccines Inc. announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine ], the only 3-antigen hepatitis B vaccine approved in Europe.